Technical Analysis for TEVA - Teva Pharmaceutical Industries

Grade Last Price % Change Price Change
grade D 18.82 0.32% 0.06
TEVA closed up 0.32 percent on Friday, January 18, 2019, on 42 percent of normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Up
See historical TEVA trend table...

Date Alert Name Type % Chg
Jan 18 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Jan 18 MACD Bullish Centerline Cross Bullish 0.00%
Jan 18 Weak + Overbought Other 0.00%
Jan 18 Outside Day Range Expansion 0.00%
Jan 18 Wide Bands Range Expansion 0.00%
Jan 18 Overbought Stochastic Strength 0.00%
Jan 17 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.32%
Jan 17 Spinning Top Other 0.32%
Jan 17 Narrow Range Bar Range Contraction 0.32%
Jan 17 NR7 Range Contraction 0.32%

Older signals for TEVA ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes pharmaceutical products worldwide. It offers generic pharmaceutical products; and basic chemical entities, as well as specialized product families, such as sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances. The company's principal branded pharmaceutical products comprise Copaxone for multiple sclerosis; Provigil and Nuvigil for the treatment of excessive sleepiness associated with narcolepsy, obstructive sleep apnea, and shift work disorders; Azilect for the treatment of Parkinson's disease; Fentora and Actiq for the treatment of pain in opioid-tolerant adult patients with cancer; Amrix for muscle spasm in acute, painful, and musculoskeletal conditions; ProAir for the treatment of bronchial spasms; Qvar for long-term control of chronic bronchial asthma; and Qnasl Nasal Aerosol for seasonal nasal and year-round nasal allergy symptoms. The company also offers Treanda for the treatment of chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma; Tevagrastim/Ratiograstim that stimulate the production of white blood cells; Eporatio, which stimulates the production of red blood cells; Synribo for chronic myeloid leukemia; Plan B One-Step for emergency oral contraception; ParaGard, a non hormonal intrauterine contraceptive; hormone therapies for menopause/perimenopause; Enjuvia for vasomotor symptoms associated with menopause; and therapies for infertility and urinary incontinence. In addition, it produces active pharmaceutical ingredients in the areas of respiratory, cardiovascular, anti-cholesterol, central nervous system, dermatological, hormones, anti-inflammatory, oncology, immunosuppressants, and muscle relaxants. Further, the company distributes third party products. It has collaborative agreements with Lonza Group Ltd. and OncoGenex Pharmaceuticals, Inc. The company was founded in 1901 and is headquartered in Petach Tikva, Israel.
Is TEVA a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 3 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 25.96
52 Week Low 14.59
Average Volume 11,383,334
200-Day Moving Average 21.2076
50-Day Moving Average 19.4612
20-Day Moving Average 17.066
10-Day Moving Average 18.346
Average True Range 0.6817
ADX 27.48
+DI 28.8563
-DI 18.5037
Chandelier Exit (Long, 3 ATRs ) 17.1049
Chandelier Exit (Short, 3 ATRs ) 16.6351
Upper Bollinger Band 19.8832
Lower Bollinger Band 14.2488
Percent B (%b) 0.81
BandWidth 33.015352
MACD Line 0.0282
MACD Signal Line -0.363
MACD Histogram 0.3912
Fundamentals Value
Market Cap 19.12 Billion
Num Shares 1.02 Billion
EPS -6.11
Price-to-Earnings (P/E) Ratio -3.08
Price-to-Sales 0.60
Price-to-Book 0.57
PEG Ratio -0.47
Dividend 1.10
Dividend Yield 5.84%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 19.42
Resistance 3 (R3) 19.38 19.15 19.32
Resistance 2 (R2) 19.15 18.99 19.17 19.29
Resistance 1 (R1) 18.98 18.90 18.87 19.02 19.25
Pivot Point 18.75 18.75 18.69 18.77 18.75
Support 1 (S1) 18.58 18.59 18.47 18.62 18.39
Support 2 (S2) 18.35 18.50 18.37 18.35
Support 3 (S3) 18.18 18.35 18.32
Support 4 (S4) 18.22